Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:36:27.931Z.
Calculation as of: 2026-10-06T17:36:27.931Z.
Quote observation: 2026-10-06T17:35:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 31946573a42b73cd13b381604bc2f467f5098c78190e00cee0d2639f3054c777
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
4D Molecular Therapeutics, Inc.
Market Cap
$664.43M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$664.32M
Price/OCF Ratio
14.40
TTM Avg
11.83
3Y Avg
25.95
5Y Avg
25.95
Market Cap
$656.39M
Price/OCF Ratio
2001.18
TTM Avg
1890.32
3Y Avg
1890.32
5Y Avg
1890.32
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $664.43M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $664.32M | 14.40 | 11.83 | 25.95 | 25.95 |
| Annexon, Inc. (ANNX)vs › | $665.18M | N/A | N/A | N/A | N/A |
| Starling Oncology, Inc. (STLN)vs › | $656.39M | 2001.18 | 1890.32 | 1890.32 | 1890.32 |
| Helus Pharma Inc. (HELP)vs › | $672.22M | N/A | N/A | N/A | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $676.84M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $640.56M | N/A | 72.20 | 236.60 | 236.60 |
| SOPHiA GENETICS S.A. (SOPH)vs › | $635.88M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $681.62M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $633.55M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
